Oranje A P, Stalder J F, Taïeb A, Tasset C, de Longueville M
Department of Dermato-Venereology (Pediatric Dermatology Unit), Rotterdam, The Netherlands.
Pediatr Allergy Immunol. 1997 Feb;8(1):28-34. doi: 10.1111/j.1399-3038.1997.tb00139.x.
The ETAC (Early Treatment of the Atopic Child) study, a multi-national double-blind placebo-controlled randomized trials, has been in progress since 1994. Fifty-six centers in Europe and Canada participate in this study. A total of 817 children with atopic dermatitis [AD] were recruited. The severity of AD was scored using the SCORAD (objective criteria). Ninety-eight investigators (mostly pediatricians) were trained by three members of the European Task Force on Atopic Dermatitis [ETFAD] to standardize their objective SCORAD scoring (system developed by the ETFAD). The experts selected photographs and prepared a training atlas. The percentages of photographs assessed by the 98 non-expert investigators below, within and above the range of evaluations by the three experts were calculated. Taking over and underscoring together, edema/papulation was the easiest intensity item to score (82% within the range by the experts). The global symptom score, as well as lichenification, edema/papulation, oozing and excoriation registered by physicians with dermatological experience were not statistically significantly different from those by other. Erythema was statistically significantly better scored by those with dermatological experience. The results of the Euclidean Distance method showed that the item excoriations gave the largest distance. Erythema and excoriations were scored better by dermatologically experienced physicians (t-test, p = 0.042 and p = 0.063 respectively), but lichenification was better scored by non-dermatologically experienced physicians (p = 0.013). The extent of surface area involved in the disease was calculated on 3 sets of photographs. Most evaluations by the 98 nonexpert investigators were within the range of the experts. Dermatologically experienced physicians scored significantly better than the others (t-test, p = 0.006). This training program is useful for standardizing the scoring in AD and indicates that SCORAD can be used by investigators from different disciplines.
ETAC(特应性儿童早期治疗)研究是一项多国双盲安慰剂对照随机试验,自1994年以来一直在进行。欧洲和加拿大的56个中心参与了这项研究。共招募了817名特应性皮炎[AD]患儿。使用SCORAD(客观标准)对AD的严重程度进行评分。98名研究人员(主要是儿科医生)由欧洲特应性皮炎工作组[ETFAD]的三名成员进行培训,以使其客观的SCORAD评分标准化(该系统由ETFAD开发)。专家们挑选了照片并编制了一本培训图谱。计算了98名非专家研究人员评估的照片在三位专家评估范围以下、范围内和以上的百分比。综合考虑高估和低估情况,水肿/丘疹是最容易评分的强度项目(82%在专家评估范围内)。有皮肤科经验的医生记录的总体症状评分以及苔藓化、水肿/丘疹、渗出和擦伤与其他医生记录的结果在统计学上无显著差异。有皮肤科经验的医生对红斑的评分在统计学上显著更高。欧几里得距离法的结果表明,擦伤项目的距离最大。有皮肤科经验的医生对红斑和擦伤的评分更好(t检验,p分别为0.042和0.063),但非皮肤科经验的医生对苔藓化的评分更好(p = 0.013)。根据3组照片计算疾病累及的表面积。98名非专家研究人员的大多数评估都在专家范围内。有皮肤科经验的医生的评分显著高于其他医生(t检验,p = 0.006)。该培训计划有助于使AD评分标准化,并表明不同学科的研究人员都可以使用SCORAD。